reeclampsia is a leading cause of maternal and fetal morbidity and mortality that affects 2%-7% of pregnancies. 1,2 This pregnancy-specific disorder is diagnosed in women presenting with new onset hypertension and proteinuria after 20 weeks gestation.
Methods
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews 12 and Metaanalysis of Observational Studies in Epidemiology 13 recommendations. The online-only Data Supplement contains detailed methodology for inclusion and exclusion criteria, diagnostic criteria, search strategy, article screening and selection, data abstraction and quality assessment, statistical analysis, and missing information.
Briefly, studies identified through PubMED, EMBASE, and Web of Science were stratified into ≥1 of the following time periods:
1. Before preeclampsia: FMD was measured in pregnant women who were followed until delivery to determine whether they developed preeclampsia. No participants had preeclampsia at the time of FMD testing (11-34 weeks). 2. At the time of active disease: FMD was measured after 20 weeks gestation to compare FMD in pregnant women with versus without preeclampsia at the time of the FMD test. 3. Postpartum: FMD was measured in nonpregnant women hours to years after delivery.
Studies that combined preeclampsia with gestational hypertension or chronic hypertension in pregnancy were only eligible if data for the subset of women who developed preeclampsia could be obtained. We included observational studies and baseline data from randomized controlled trials.
Statistical Analysis
The online-only Data Supplement describes detailed statistical methods. Briefly, the primary outcome was FMD, expressed as a percent change from preinflation diameter. FMD methodology is highly variable; therefore, we used the standardized mean difference (SMD) to examine differences between the preeclampsia and non-preeclampsia groups. This effect size measurement expresses the difference between group means in units of standard deviations. For each time period, the bias-corrected SMD (Hedges G) was estimated by pooling individual trial results using random-effects models via the DerSimonian-Laird method (Open Meta-analyst). Because of high heterogeneity in the effect sizes of included studies, confirmatory analyses were run in MetaEasy 14 using the Profile Likelihood method (data not shown). Simulation studies suggested that the Profile Likelihood method is more accurate for heterogeneous data. 15 
Results
We identified 610 potentially eligible articles. Of the 131 full text articles that were reviewed, 37 were selected for inclusion in the meta-analysis (Figure 1 ). This included studies that measured FMD before preeclampsia (n=12), at the time of preeclampsia (n=13), and postpartum (n=19). Postpartum studies were subdivided into early and late time periods because studies were conducted at a mean or median postpartum interval of <3 years postpartum (n=15) or >10 years postpartum (n=4). The online-only Data Supplement includes tables describing summary characteristics (Tables S1-S3 in the online-only Data Supplement), diagnostic criteria for studies examining women with more severe and less severe forms of preeclampsia (Tables S4), and exclusion criteria  (Tables S5 and S6 ). The quality assessment tool and tables describing study quality and FMD protocols are available from the authors.
Before Preeclampsia
The 12 prospective cohort studies that were selected for the meta-analysis [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] included 156 pregnant women who subsequently developed preeclampsia and 947 women who did not develop preeclampsia (Tables S1 and S5) . Two additional studies were included in the qualitative synthesis. 28, 29 Women who subsequently developed preeclampsia had lower FMD compared with women who did not develop preeclampsia. Six studies included multiple time points. 20, 21, [23] [24] [25] Results did not differ between analyses that included second trimester studies only (SMD: −0.84, 95% confidence interval [CI]: −1.19, −0.50; P<0.001; Figure 2 ), the earliest time points from all studies (SMD: −0.78, 95% CI: −1.19, −0.37; P<0.001; Figure S1A ), or the latest time points from all studies (SMD: −0.83, 95% CI: −1.30, −0.37; P<0.001; Figure  S1B ). Results were attenuated in a sensitivity analysis of studies that excluded smokers (earliest time points, SMD: −0.52, 95% CI: −1.02, −0.02; P=0.043). 19, 22, 23, 25, 27 Results were not different when a study that reported FMD as median (interquartile range) 29 was included (data not shown). The high heterogeneity for 2nd trimester studies ( Figure 2 ) was lower in sensitivity analysis in which a study examining women with systemic autoimmune disease was excluded (SMD: −0.92, 95% CI: −1.24, −0.60; P<0.001).
At the Time of Preeclampsia
The 14 cross-sectional studies that were eligible for the meta-analysis 23,30-41 included 333 preeclamptic women and 467 non-preeclamptic pregnant women (Tables S2 and  S6) . Five additional studies were included in the qualitative synthesis.
42-46
At the time of active disease, FMD was significantly lower in women who had preeclampsia (SMD: −1.41, 95% CI: −2.00, −0.83; P<0.001; Figure 3 ), compared with women who did not have preeclampsia. The analysis revealed significant heterogeneity among studies (Q=130. 4 did not alter the results. Including a study in which FMD was reported as median (interquartile range) had no effect. 45 Separate analyses were performed to examine the effects of more and less severe forms of preeclampsia (diagnostic criteria: Table S4 ). FMD was significantly lower in women with less severe forms of preeclampsia 31,34,36,37,39 compared with women who had normotensive pregnancies (SMD: −0.95, 95% CI: −1.30, −0.59; P<0.001; Figure S2A ). Similar results were observed in studies examining women with more severe forms of preeclampsia 31,34,36,39 compared with women who had normotensive pregnancies (SMD: −1.74, 95% CI: −2.65, −0.83; P<0.001; Figure S2B ).
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Early Postpartum Period
Six prospective cohort studies, 20 ,23,32,34,35,38 8 cross-sectional studies, 47-54 and 1 randomized controlled trial of exercise training 55 were eligible for the meta-analysis (Tables S3 and  S6 ). These studies included 429 women who had a history of preeclampsia and 470 women who did not have a history of preeclampsia. The randomized controlled trial was treated as a cross-sectional study because only pre-randomization brachial artery FMD data were included in the meta-analysis. Two additional studies were included in the qualitative synthesis. 46, 56 FMD was significantly lower in women with preeclampsia among studies conducted at a mean or median postpartum interval of <3 years (SMD: −0.90, 95% CI: −1.26, −0.54; P<0.001, data not shown). However, heterogeneity was high (Q= 6.9; P<0.001, I 2 =82%). Results were not different after 
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56
While all studies conducted within the first 6 months postpartum were cohort studies, all studies conducted between 6 months and 3 years postpartum were cross-sectional. FMD was significantly lower among women with a history of preeclampsia in cohort studies conducted before 6 months postpartum (SMD: −0.44, 95% CI: −0.68, −0.20; P<0.001; Figure  4A ). This effect remain significant in sensitivity analyses of Preeclampsia was also associated with a significant reduction in FMD among the studies that examined women with less severe 23,34,54 ( Figure S3A ) and more severe 23, 34, 48, 49, 54 ( Figure S3B ) forms of preeclampsia.
Late Postpartum Period
Four cross-sectional studies were eligible for the metaanalysis (Tables S3 and S6 
All Time Periods
The high heterogeneity for some of the analyses presented in this study persisted in subgroup analyses examining the effect of cohort type, blinded FMD analysis, FMD analysis method, and study quality (data not shown). Among studies conducted before preeclampsia, high heterogeneity was not explained by cohort type (with and without preeclampsia risk factors versus with at least one of several risk factors). The Profile Likelihood method may provide more accurate coverage of the overall effect estimation for data sets with high heterogeneity. Confirmatory analyses using this method gave similar results to those obtained via the DerSimonian-Laird method (data not shown).
Discussion
Our objective was to perform a meta-analysis of the studies that measured FMD before, during, or after preeclampsia to assess the role of vascular dysfunction in preeclampsia and its potential contribution to cardiovascular disease after preeclamptic pregnancies. The data showed that women who had preeclampsia, when compared with women who did not have preeclampsia, had lower FMD before the clinical diagnosis of preeclampsia (≈20-29 weeks gestation), at the time of preeclampsia, and for 3 years postpartum. Sensitivity analyses showed similar results when the analysis was limited to studies that excluded smokers, women with chronic hypertension, or both. Significantly lower FMD was observed among women with less severe and more severe forms of preeclampsia, both at the time of disease and within the first 3 years postpartum. These results are consistent with the hypothesis that vascular dysfunction precedes the onset of disease in women with preeclampsia risk factors. They also suggest that vascular dysfunction may contribute to the pathophysiology of preeclampsia. Persistent vascular changes after preeclamptic pregnancies may represent a mechanistic link with increased risk for future cardiovascular disease in these women.
Although FMD is a vascular function test, it is also an established method of evaluating future cardiovascular disease risk in research studies. Low brachial artery FMD predicts cardiovascular event risk in healthy populations and in patients with cardiovascular disease.
62-65 A recent meta-analysis concluded that for every 1% increase in brachial artery FMD, the relative risk of cardiovascular events was 0.87 (95% CI 0.83 to 0.91). 11 Lower FMD in the preeclampsia group was a consistent finding across studies and time periods, despite differences in study designs, patient populations, and FMD protocols. The high heterogeneity in some analyses was explained by variations in the magnitude of the effect, rather than the direction.
Although most studies conducted at the time of preeclampsia and postpartum excluded women with comorbidities (ie, chronic hypertension, diabetes mellitus, cardiovascular or renal disease), studies conducted before pregnancy included women with a variety of risk factors and co-morbidities. Studies that reported lower FMD in women with a history of preeclampsia recruited women with at least one preeclampsia risk factor, 16, [18] [19] [20] enriched their sample with women who had at least one preeclampsia risk factor, 23 or enrolled women with a normal versus abnormal uterine artery Doppler velocimetry test in mid-pregnancy. 17, 26 Four studies found no differences in FMD between women who developed preeclampsia compared with women who did not have preeclampsia. Two of these studies did not select or enrich their samples with women who had preeclampsia risk factors.
22,27 The other 2 studies enrolled women with a single risk factor (long duration type 1 diabetes mellitus, 21 systemic autoimmune disease 24 ). These high-risk women may have had endothelial dysfunction 66,67 before pregnancy. Additional studies conducted before conception and in early pregnancy are needed to determine whether the vascular dysfunction observed before preeclampsia is because of pre-existing maternal risk factors or is attributable to early stages in the disease process.
There are several possible explanations for the finding that vascular dysfunction in women with preeclampsia does not resolve during the first 3 years postpartum. Women who have had preeclampsia may have persistent endothelial dysfunction because of risk factors that pre-dated the pregnancy. Alternatively, preeclampsia could also worsen other cardiovascular risk factors, increasing a women's risk of future hypertension and cardiovascular disease. Finally, preeclampsia may cause lasting damage to the heart and vasculature. If preeclampsia causes lasting damage that contributes to future 6 Hypertension February 2016 cardiovascular disease, then treatment goals may need to be adjusted to prevent or mitigate this damage. Unexpectedly, a small number of studies suggest that lower FMD in women with a history of preeclampsia was no longer apparent by 10 years postpartum. These results should be interpreted with caution because they are based on 4 studies and include fewer women than studies conducted at other time periods. A meta-analysis published in 2005 found that although FMD was related to cardiovascular risk factors in low risk populations, no association was observed in mediumand high-risk populations. 68 The authors postulated that FMD may not reflect endothelial dysfunction accurately in high-risk patients with stiffer brachial arteries. These findings suggest that the lack of a relationship between FMD and preeclampsia at 10 years postpartum could be related to an increase in their cardiovascular burden. However, a second meta-analysis conducted in 2013 reported that FMD was predictive of future cardiovascular events in both asymptomatic and diseased populations.
69 Although the present meta-analysis focused on FMD, other vascular function tests or markers may yield different results. This meta-analysis sets the stage for future studies aiming to understand the trajectory of and mechanisms regulating changes in vascular health beyond 3 years postpartum. Finally, studies that report 2 additional measurements that are derived from the FMD test, low flow-mediated constriction and the shear stimulus for FMD, are needed. Combining these 3 measurements may provide additional insight into the nature and location of vascular dysfunction. 10 This meta-analysis highlights several limitations of the current literature, which include the following:
• Publication bias: All papers were small observational studies. Negative studies may not have been published. Mitigation strategy: We included abstracts and unpublished data.
• Referral bias: Patients with pre-existing conditions or severe forms of preeclampsia may be over-represented because most studies were conducted at tertiary care or teaching hospitals. Mitigation strategy: Most studies conducted at the time of preeclampsia or postpartum excluded women with co-morbidities.
• Nonrepresentative samples in studies conducted before preeclampsia: Most studies conducted before preeclampsia exclusively enrolled or enriched their samples with women with co-morbidities or risk factors. Recent guidelines outlined the problems with this approach.
70
• Pre-existing risk factors: Current guidelines recommend that studies focusing on prediction, prevention, treatment, or mechanisms of preeclampsia account for obesity, smoking, and fetal sex. 70 Many studies reported a higher average body mass index in the preeclampsia group, which may contribute to vascular dysfunction before conception. Future studies should clarify the relative contributions of pre-existing maternal risk factors, versus damage caused by preeclampsia, to vascular dysfunction in women with preeclampsia. No studies examined the relationship between FMD and fetal sex. Mitigation Strategy: Sensitivity analyses of studies that excluded smokers yielded similar results.
• FMD methodology: Most studies used older protocols, in which differences in FMD may be an artifact of the time selected for post-release diameter measurement.
71,72
Percent FMD may underestimate FMD in large arteries and overestimate FMD in small arteries. 73 Recently proposed allometric scaling techniques may address this problem; however, they are heavily debated in the FMD literature. [74] [75] [76] No studies examined allometrically scaled FMD.
When compared with women who did not develop preeclampsia, women with pre-existing risk factors who later developed preeclampsia had lower FMD before the clinical diagnosis of disease (≈20-29 weeks gestation). Women with preeclampsia also had lower FMD at the time of preeclampsia and within the first 3 years postpartum. Similar results were observed when the analysis was limited to studies that excluded women with chronic hypertension, smokers, or both. A few studies suggested that lower FMD in women with a history of preeclampsia was no longer evident by 10 years postpartum; however, more research is needed.
Perspectives
These results of this meta-analysis are consistent with the hypothesis that vascular dysfunction may contribute to the pathophysiology of preeclampsia and does not resolve in the first 3 years postpartum. Further studies should determine whether women without pre-existing risk factors have vascular dysfunction before developing preeclampsia and clarify whether vascular dysfunction persists beyond 3 years postpartum in women with a history of preeclampsia. These studies will set the stage for novel cardiovascular risk markers and early prevention and treatment strategies for women who have had preeclampsia. What Is New?
• When compared with women who did not have preeclampsia, women who had preeclampsia had lower flow-mediated dilation before the clinical diagnosis of preeclampsia, at the time of diagnosis and for 3 years postpartum.
What Is Relevant?
• Women with a history of preeclampsia have underlying endothelial dysfunction, as measured by flow-mediated dilation. This may translate into elevated cardiovascular risk later in life.
Summary
A meta-analysis of studies of flow-mediated dilation in preeclampsia indicates that endothelial dysfunction may be mechanistically related to both the pathophysiology preeclampsia and to elevated future cardiovascular disease risk in the affected women. 
Inclusion and Exclusion Criteria:
We examined studies that compared FMD among women who had preeclampsia and women who had pregnancies that were not complicated by preeclampsia. Studies were eligible for inclusion if FMD was measured non-invasively by Bmode ultrasound and expressed as an absolute or percent change in artery diameter. Dilation had to be induced by ischemia without simultaneous pharmacological or physical stimuli. We excluded studies that i) examined shear-mediated dilation in vitro, ii) performed in vivo measurements of shear-mediated dilation using other techniques, iii) used non-ischemic stimuli to induce dilation and iv) papers that did not include original data.
Diagnostic Criteria:
In studies for which diagnostic criteria were listed in the paper or provided by the study authors, preeclampsia was diagnosed according to accepted guidelines (International Society for the Study of Hypertension in Pregnancy, Report of the National High Blood Pressure Program Working Group, or old guidelines from the American College of Obstetricians and Gynecologists), or using equivalent criteria for hypertension and proteinuria appearing after 20 weeks gestation. The new guidelines for clinical preeclampsia diagnosis recently released by the American College of Obstetricians and Gynecologists, which allow preeclampsia to be diagnosed in women without proteinuria if other severe features are present, were applied retrospectively to diagnose preeclampsia for one patient in one study. 1 Exclusion of this study did not affect the results of the meta-analysis.
Studies were stratified into one or more of the following time periods:
1. Before preeclampsia: FMD was measured in pregnant women who were followed until delivery to determine whether they developed preeclampsia. No participants had preeclampsia at the time of the FMD test. 2. At the time of preeclampsia: FMD was measured after 20 weeks gestation, to compare FMD in pregnant women with vs. without a diagnosis of preeclampsia at the time of the FMD test. 3. Post-partum: FMD was measured in non-pregnant women hours to years after delivery. Studies that combined preeclampsia with gestational hypertension and/or chronic hypertension in pregnancy were only eligible if data for the subset of women who developed preeclampsia could be obtained from the study authors. We included observational studies and baseline data from randomized controlled trials.
Search Strategy and Selection:
A vascular physiologist (TLW) and biostatistician with expertise in conducting systematic reviews and meta-analyses (NMM) developed the search strategy. We searched PubMED, EMBASE and Web of Science through May 29, 2015 for studies containing key words for FMD and preeclampsia (FMD, or flow mediated dilation, or flow mediated dilatation, or flow mediated vasodilation, or flow mediated vasodilatation, or flow associated dilat*, or flow associated vasodilat*, or flow dependent dilat*, or flow dependent vasodilat*, or endothelium dependent vasodilatation, or endothelium mediated vasodilat*, or brachial artery reactivity, or brachial artery dilation, or brachial artery dilatation, or flow mediated constriction, or shear stress, or brachial artery/ultrasonography) and (preeclampsia, or pre-eclampsia, or pre-eclamptic, or pregnancy hypertension, or hypertensive pregnancy disorders, or pregnancy-induced hypertension). There were no restrictions on publication language or status. Authors of relevant abstracts were contacted to identify eligible unpublished datasets. We manually searched reference lists of papers that were included in the analysis, as well as relevant reviews and editorials. We also asked content experts to provide information on potentially eligible studies.
Article Screening and Selection: Two reviewers (TLW, JML) independently evaluated the eligibility of all titles and abstracts identified through PubMED, EMBASE and Web of Science. Studies were included in the full text screening if either reviewer identified the study as being potentially eligible, or if the abstract and title did not include sufficient information. Studies were eligible for full text screening if they included any non-invasive vascular test and women with any form of hypertension in pregnancy. Abstracts that did not mention preeclampsia but included women with pregnancy complications that are associated with preeclampsia were also eligible for full-text screening (pre-term birth, intrauterine growth restriction, gestational diabetes). Noninvasive vascular tests indicating that full-text screening was required included flow-mediated dilation, venous occlusion plethysmography, pulse wave velocity, augmentation index, uterine or umbilical artery Doppler, Endo-PAT, iontophoresis, vascular resistance, carotid intima-media thickness, other ultrasound, echocardiography or vascular function studies. Hypertension in pregnancy included gestational hypertension, preeclampsia, chronic hypertension and chronic hypertension with superimposed preeclampsia. The same reviewers independently performed full text screening to select articles for inclusion (97% agreement, kappa = 0.98) according to the criteria listed under Inclusion and Exclusion Criteria (supplemental methods). Disagreements were resolved by consensus (TLW, JML) or arbitration (NMM).
Data Abstraction and Quality Assessment: Two reviewers independently abstracted the following data: 1) Study design, 2) Inclusion and exclusion criteria, 3) Criteria for preeclampsia diagnosis, 4) Time period, 5) FMD methodology and 6) FMD and its two companion measurements, the shear stimulus for FMD and low flow-mediated constriction (LFMC). LFMC refers to the change in diameter from pre-inflation baseline to the end of cuff occlusion. 2 Combining FMD, LFMC and the shear stimulus may provide additional insight into the nature and location of vascular dysfunction. 3 Each reviewer independently evaluated the quality of selected manuscripts using an adapted version of the Newcastle-Ottawa tool for observational studies (available from authors upon request). 4 Independent reviewers used standardized forms and protocols when selecting and abstracting data. Authors were contacted to clarify and confirm the accuracy of abstracted data.
Statistical Analysis: The primary outcome was FMD, expressed as a percent change from preinflation diameter. Methodologies for measuring FMD are highly variable; therefore we used the standardized mean difference (SMD) to examine differences between the preeclampsia and nonpreeclampsia groups. This measurement of effect size expresses the difference between group means in units of standard deviations. For each time period, the bias-corrected SMD (Hedges G) was estimated by pooling individual trial results using random-effects models via the DerSimonian-Laird method (Open Meta-analyst). Heterogeneity was assessed using a Cochran q test, I
2 statistic, and heterogeneity score H 2 . Q-test values for each meta-analysis were converted into H 2 values. H 2 is the heterogeneity measure least affected by the number of studies in the analysis, and it can be defined as: H 2 = Q/k-1 (where k is number of included studies). H 2 has a value of 1 in the case of homogeneity. Heterogeneity is assumed to be present when H 2 > 1. Due to high heterogeneity in effect sizes of included studies, confirmatory analyses were run in MetaEasy 5 using the Profile Likelihood method (data not shown). Previously published simulation studies suggested that, in the presence of heterogeneity, the Profile Likelihood method provides the most accurate coverage of the overall effect estimation. 6 A separate forest plot was constructed for each analysis showing the SMD (box), 95% confidence interval (lines), and weight (size of box) for each trial. The diamond shows the overall effect size. A p value <0.05 was considered to be statistically significant. In each time period, separate analyses were performed to examine the effects of milder forms of preeclampsia (i.e. late onset or mild preeclampsia, or preeclampsia in a single pregnancy) and more severe forms of preeclampsia (i.e. early onset, severe, or recurrent preeclampsia). During the post-partum period, separate analyses were performed for studies with a median post-partum interval of less than 3 years vs. more than 10 years post-partum.
Subgroup analyses were performed to examine the potential effects of different populations, time periods, methodologies and study quality. These include: 1) Study type (cross-sectional vs. cohort), 2) Population in cohort studies (studies that included both high and low risk cohorts vs. studies that examined a high risk cohort of women with at least one of several pre-defined risk factors), 3) Median post-partum interval (<6 months vs. 6 months to 3 years), 4) Blinded FMD analysis (blinded vs. not blinded vs. unknown), 5) Diameter measurement method (automated analysis of continuous diameter data vs. manual ECG gated analysis with post-release diameter measured at ≥1 time point(s) vs. manual analysis), 6) Quality (score ≥ 6 vs. <6).
Sensitivity analyses were conducted to examine the effects of 1) measurements at different time points in cohort studies conducted prior to preeclampsia, 2) the inclusion of unpublished data and 3) the exclusion of studies that included smokers or women with chronic hypertension, and 4) the inclusion of studies that presented FMD as median (IQR). One study in each time period (n=4) [7] [8] [9] [10] reported medians and interquartile ranges (IQR) because FMD data were not normally distributed. These studies were excluded. However, as the DerSimonian-Laird method is highly robust against even very severe violations of the assumption of normally distributed effect sizes, 6 we performed sensitivity analyses to verify that including these studies would not have changed the results. For the purpose of sensitivity analyses, the median was used to approximate the mean, while the SD was estimated as IQR/1.35. 
